Small cell lung cancer (SCLC) is the most aggressive lung cancer subtype and little progress has been made in understanding the molecular mechanisms causing this devastating disease. No mechanistic explanation exists for a central clinical hallmark: While SCLC typically presents with initial sensitivity against chemotherapy, the disease almost inevitably relapses. Recent discoveries in SCLC genomics and transcriptomics have now provided first mechanistic insight into the biology of this deadly disease. 

Latest Publications

  • Landscape of G-quadruplex DNA structural regions in breast cancer.
    Hänsel-Hertsch R, Simeone A, Shea A, Hui WWI, Zyner KG, Marsico G, Rueda OM, Bruna A, Martin A, Zhang X, Adhikari S, Tannahill D, Caldas C, Balasubramanian S.
    Nat Genet. 2020 Sep;52(9):878-883. doi: 10.1038/s41588-020-0672-8. Epub 2020 Aug 3.
    PMID: 32747825
  • Integrin activation enables simultaneous and sensitive detection of functional virus-specific CD4+ and CD8+ T cells.
    Anna Schöllhorn, Juliane Schuhmacher, Luciana Besedovsky, Rolf Fendel, Anja T.R. Jensen,  Stefan Stevanović, Tanja Lange, Hans-Georg Rammensee, Jan Born, Cécile Gouttefangeas, Stoyan Dimitrov
    Research Square
    DOI: 10.21203/rs.3.rs-67111/v1
  • Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy.
    Klein S, Quaas A, Noh KW, Cartolano M, Abedpour N, Mauch C, Quantius J, Reinhardt HC, Buettner R, Peifer M, Helbig D.
    Clin Cancer Res. 2020 Aug 17. doi: 10.1158/1078-0432.CCR-20-1899.
    PMID: 32817080